Boston Scientific Corporation’s BSX successful result from its WHISPER randomized controlled trial (RCT) further boosts its neuromodulation business. This announcement follows the recent FDA approval ...
Dublin, May 14, 2024 (GLOBE NEWSWIRE) -- The "Neuromodulation Devices Market Size and Forecasts 2020 - 2030, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, ...
MILAN & BERLIN--(BUSINESS WIRE)--WISE Srl, a medical device company developing next-generation implantable leads for neuromonitoring, neuromodulation and brain-machine interfacing, today announced the ...
DUBLIN--(BUSINESS WIRE)--The "Neuromodulation Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering. Neuromodulation is an intracranial, ...
St. Jude gets FDA approval for tiniest MRI-compatible, upgradeable, spinal-cord pain neurostimulator
Protégé MRI spinal cord stimulation (SCS) system--Courtesy of St. Jude Medical The FDA has approved the Protégé MRI spinal cord stimulation (SCS) system to treat ...
Abbott announced new five-year data demonstrating that its neuromodulation therapies, including its proprietary BurstDR spinal cord stimulation (SCS) waveform and dorsal root ganglion stimulation ...
Prominent players in the neuromodulation market include Medtronic (Ireland), Boston Scientific Corporation (US), Abbott (US), LivaNova PLC (UK), Nevro Corp (US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results